Amgen sets to offer a competitor to Roche's Avastin.
Pharma giant aims to develop cancer drug delivery technology. Halozyme shares are up more than 16% in pre-market trading.
In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000.
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat